TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9545876

Group type: EXPERIMENTAL
Intervention: Prime & Bond 2.0
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose Plus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2 (30 seconds application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2 (60 seconds application)
Number of subjects: 0
Study: 1771934

Group type: EXPERIMENTAL
Intervention: omeprazole 40 mg/d for 4 weeks (n = 13)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: omeprazole plus BSS for 4 weeks (n = 13)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)
Number of subjects: 50
Study: 7137520

Group type: EXPERIMENTAL
Intervention: Microcrystallinic theophylline
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Theolair
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nuelin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Teovent
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oxyphylline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Terbutaline inhalations (5 doses)
Number of subjects: 8
Study: 30217374

Group type: EXPERIMENTAL
Intervention: One-catheter concepts (OCC) using Tiger II or BLK catheters
Number of subjects: 300

Group type: COMPARATOR
Intervention: Two-catheter concepts (TCC) using standard Judkins catheters
Number of subjects: 300
Study: 26227996

Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - energy intake subscale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - energy expenditure subscale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - self-monitoring subscale
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Strategies for Weight Management measure (SWM) - self-regulation subscale
Number of subjects: 404
Study: 24894410

Group type: EXPERIMENTAL
Intervention: Freeze-dried broccoli sprouts (90 mg of active sulforaphane, 15 capsules per day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (inactive substances, mainly methylcellulose, same capsule size and portion distribution)
Number of subjects: 40
Study: 22277664

Group type: EXPERIMENTAL
Intervention: 3 ml kg(‐1) diluted raspberry syrup
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 7 ml kg(‐1) diluted raspberry syrup
Number of subjects: 14
Study: 20625111

Group type: EXPERIMENTAL
Intervention: Enalapril (target dose 0.4 mg . kg(‐1) . d(‐1))
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 230
Study: 18563971

Group type: EXPERIMENTAL
Intervention: Listening
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Singing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Rhythm tapping
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Keyboard playing
Number of subjects: 32
Study: 15793606

Group type: EXPERIMENTAL
Intervention: HR 0‐(beta‐hydroxyethyl)‐rutosides (1 g/day)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: HR 0‐(beta‐hydroxyethyl)‐rutosides (2 g/day)
Number of subjects: 22
Study: 11989827

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 60

Group type: COMPARATOR
Intervention: Open fundoplication
Number of subjects: 60
Study: 10431768

Group type: EXPERIMENTAL
Intervention: Interferon-beta1a treatment
Number of subjects: 68
Study: 7593528

Group type: EXPERIMENTAL
Intervention: 0.5 mg gemeprost by vaginal pessary (group I)
Number of subjects: 800

Group type: COMPARATOR
Intervention: 600 micrograms misoprostol by mouth (group II)
Number of subjects: 800

Group type: COMPARATOR
Intervention: 600 micrograms misoprostol (group II)
Number of subjects: 800
Study: 2259825

Group type: EXPERIMENTAL
Intervention: Fenoterol (2.5 mg) with saline to complete 3 ml given through a jet nebulizer; followed by an additional dose (1 mg) through a 500 ml spacer 30 minutes later
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fenoterol (2.5 mg) with saline to complete 3 ml given through a spacer first; followed by an additional dose (1 mg) through a jet nebulizer 30 minutes later
Number of subjects: 44
Study: 6777705

Group type: EXPERIMENTAL
Intervention: 40% Sorbitol
Number of subjects: 53

Group type: COMPARATOR
Intervention: 20% Mannitol
Number of subjects: 53
Study: 6357964

Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate tablets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 40
Study: 31325625

Group type: EXPERIMENTAL
Intervention: TIVAD
Number of subjects: 141

Group type: COMPARATOR
Intervention: BKP
Number of subjects: 141
Study: 30572939

Group type: EXPERIMENTAL
Intervention: CCRT + TME
Number of subjects: 192

Group type: COMPARATOR
Intervention: TME
Number of subjects: 192
Study: 27124116

Group type: EXPERIMENTAL
Intervention: Left temporal area anodal (LTA) or bifrontal tDCS stimulation (2 mA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham stimulation (0.3 mA)
Number of subjects: 43
Study: 25125014

Group type: EXPERIMENTAL
Intervention: Proximal balloon occlusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Patients with new cerebral ischemic lesions on DW-MRI
Number of subjects: 100

Group type: COMPARATOR
Intervention: Patients without DW-MRI lesions
Number of subjects: 100
Study: 22674146

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) - epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) for 4 cycles (EC-T)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hormone therapy (HT) - exemestane 25 mg daily for 24 weeks (combined with goserelin in premenopausal patients)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Hormone therapy (HT)
Number of subjects: 95
Study: 20237055

Group type: EXPERIMENTAL
Intervention: Bismuth-film-coated catheter (FCC)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Standard catheter (SC)
Number of subjects: 77
Study: 18773752

Group type: EXPERIMENTAL
Intervention: Intentional weight loss (specific details not provided)
Number of subjects: 0
Study: 16214025

Group type: EXPERIMENTAL
Intervention: Mental tasks (psychological stress)
Number of subjects: 32
Study: 11844818

Group type: EXPERIMENTAL
Intervention: RT plus weekly CDDP chemotherapy (40 mg/m(2))
Number of subjects: 259

Group type: COMPARATOR
Intervention: RT without chemotherapy
Number of subjects: 259
Study: 10076721

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by adjusted locoregional treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial mastectomy followed by adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study: 7672547

Group type: EXPERIMENTAL
Intervention: Nd: YAG laser therapy
Number of subjects: 94

Group type: COMPARATOR
Intervention: Injection-assisted piecemeal polypectomy
Number of subjects: 94
Study: 2145233

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 40
Study: 6102561

Group type: EXPERIMENTAL
Intervention: Increased psychiatrist/patient ratio
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decongesting the clinic
Number of subjects: 0
Study: 31880343

Group type: EXPERIMENTAL
Intervention: VASE RESOLVE
Number of subjects: 0

Group type: COMPARATOR
Intervention: RESOLVE with SMS
Number of subjects: 0
Study: 30987987

Group type: EXPERIMENTAL
Intervention: Group exercise and socialisation/health education + GAR (hearing education, communication strategies, psychosocial support)
Number of subjects: 71

Group type: COMPARATOR
Intervention: GAR only
Number of subjects: 71
Study: 27996339

Group type: EXPERIMENTAL
Intervention: Bowen systemic family therapy (eight 90‐minute sessions)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 42
Study: 26188742

Group type: EXPERIMENTAL
Intervention: Small bites technique (5 mm every 5 mm)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Large bites technique (1 cm every 1 cm)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Small bites technique
Number of subjects: 560

Group type: COMPARATOR
Intervention: Large bites technique
Number of subjects: 560
Study: 23200124

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate treatment (PCT) ≥50 g oral carbohydrates 2-4 h pre-anaesthesia
Number of subjects: 1685

Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate treatment (PCT)
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Control (fasted/placebo)
Number of subjects: 1685
Study: 19542525

Group type: EXPERIMENTAL
Intervention: Ziprasidone (80-160 mg/d)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Olanzapine (10-20 mg)
Number of subjects: 76
Study: 18716688

Group type: EXPERIMENTAL
Intervention: 80 mg tobramycin twice‐daily continuous treatment
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 300 mg tobramycin twice daily in cycles of 28 days on and 28 days off treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Colistin (control group)
Number of subjects: 32
Study: 17152857

Group type: EXPERIMENTAL
Intervention: Midodrine (5 mg orally) given to female subjects 1 hour before post-TST
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo given to female subjects 1 hour before post-TST
Number of subjects: 29
Study: 15314393

Group type: EXPERIMENTAL
Intervention: SP6 acupressure
Number of subjects: 58

Group type: COMPARATOR
Intervention: SP6 touch
Number of subjects: 58
Study: 10790044

Group type: EXPERIMENTAL
Intervention: On-frequency condition (using signals from stage I to mask probes of the same frequency)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Off-frequency condition (using off-frequency maskers at levels determined in stage I to mask probes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined condition (using both on- and off-frequency maskers to mask probes)
Number of subjects: 0
Study: 9311145

Group type: EXPERIMENTAL
Intervention: Unrestricted consequences (cursor moves freely with joystick)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Restricted consequences (cursor confined to track)
Number of subjects: 0
Study: 8287567

Group type: EXPERIMENTAL
Intervention: Biosynthetic GH replacement therapy (0.25 IU/kg/week)
Number of subjects: 20
Study: 2882294

Group type: EXPERIMENTAL
Intervention: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma), given by intravenous infusion twice a week for four weeks
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 1 microgram, 30 micrograms, or 1000 micrograms doses of recombinant gamma interferon (IFN‐gamma)
Number of subjects: 18
Study: 31385885

Group type: EXPERIMENTAL
Intervention: Pinaverium Bromide 100 mg plus Simethicone 300 mg (PB+S)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 30141237

Group type: EXPERIMENTAL
Intervention: Low dose (2 mg/day) of aripiprazole adjunctive to antidepressant therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29119110

Group type: EXPERIMENTAL
Intervention: Diosmin (50mg/kg/day)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 20% 250ml mannitol (1g/kg/day) for 7 days and dexamethasone (10mg/day) for 3 days intravenously
Number of subjects: 150
Study: 26316698

Group type: EXPERIMENTAL
Intervention: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets (one tablet), 15/650mg (two tablets), or 30/1,300mg (four tablets) under fasted conditions
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Biphasic immediate-release/extended-release oxycodone/acetaminophen 7.5/325mg tablets under fed conditions
Number of subjects: 151
Study: 24079037

Group type: EXPERIMENTAL
Intervention: Salbutamol and dexamethasone added into WLL fluid
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (0.9% sodium chloride solution in WLL)
Number of subjects: 176
Study: 20076856

Group type: EXPERIMENTAL
Intervention: G-CSF (10 microg/kg)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 18194028

Group type: EXPERIMENTAL
Intervention: Video‐feedback Intervention to promote Positive Parenting and Sensitive Discipline (VIPP‐SD)
Number of subjects: 157
Study: 16387583

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (100 mug twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Montelukast (5-10 mg nightly, age dependent)
Number of subjects: 0
Study: 15057400

Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (Group B)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 19

Group type: COMPARATOR
Intervention: No pre‐medication (Group A)
Number of subjects: 19
Study: 11127161

Group type: EXPERIMENTAL
Intervention: Bupropion (Zyban-GlaxoWellcome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 0
Study: 8985043

Group type: EXPERIMENTAL
Intervention: LDR interstitial radiotherapy (70 Gy/4 to 9 days)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HDR interstitial radiotherapy (60 Gy/10 fractions/6 days)
Number of subjects: 29
Study: 1473653

Group type: EXPERIMENTAL
Intervention: Tc-99m-teboroxime
Number of subjects: 16

Group type: COMPARATOR
Intervention: TI-201
Number of subjects: 16
Study: 3882899

Group type: EXPERIMENTAL
Intervention: Pentobarbital treatment (27 cases)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (26 cases)
Number of subjects: 53
Study: 30326271

Group type: EXPERIMENTAL
Intervention: Operant Learning (OL)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Energy Conservation (EC)
Number of subjects: 178
Study: 30452207

Group type: EXPERIMENTAL
Intervention: New value frameworks incorporating real-world evidence
Number of subjects: 0
Study: 25796578

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 625

Group type: EXPERIMENTAL
Intervention: Face-to-face counseling
Number of subjects: 625

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 625
Study: 24669750

Group type: EXPERIMENTAL
Intervention: Flaxseed + Anastrozole (AI)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anastrozole (AI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 22053074

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Transdermal GTN (0.6 mg/h)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Rosiglitazone + GTN
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Co-infusion of antioxidant vitamin C with rosiglitazone and GTN
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20473738

Group type: EXPERIMENTAL
Intervention: Tanreqing Injection (TRQI)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group A (15 mg ambroxol hydrochloride twice a day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group B (conventional Western medicine treatment only)
Number of subjects: 90
Study: 18269068

Group type: EXPERIMENTAL
Intervention: Treatment strategies for patients with acute decompensated heart failure and poor renal function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sildenafil (Viagra) for patients with heart failure and preserved left ventricular systolic function
Number of subjects: 0
Study: 16294264

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 9496

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9496
Study: 12412806

Group type: EXPERIMENTAL
Intervention: Once-weekly alendronate 70 mg
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: Twice-weekly alendronate 35 mg
Number of subjects: 1258

Group type: COMPARATOR
Intervention: Daily alendronate 10 mg
Number of subjects: 1258

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 1258
Study: 10902536

Group type: EXPERIMENTAL
Intervention: 500ml of fresh milk (620mg Ca)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Test meal (250g curd, 150g yoghurt, 3 slices pineapple, 2 breakfast rolls, 2 cups of coffee, 10g coffee cream, 20g butter, 50g jam, 20g honey; 580mg Ca)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lactogluconate effervescent tablet (500mg Ca)
Number of subjects: 8
Study: 7595245

Group type: EXPERIMENTAL
Intervention: Orthographic similarity (e.g., keller‐KELLER, cellar‐ladle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphological relatedness (e.g., kellen‐KELLE, ladles‐ladle)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphological similarity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Form similarity
Number of subjects: 0
Study: 1487608

Group type: EXPERIMENTAL
Intervention: Octreotide 25 micrograms/h for 24 h after an initial bolus of 100 micrograms
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vasopressin 0.4 U/min for 24 h
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vasopressin
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mortality related to bleeding esophageal varices
Number of subjects: 48
Study: 3711379

Group type: EXPERIMENTAL
Intervention: Oral 8‐methoxypsoralen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bath-water delivery of 8‐methoxypsoralen
Number of subjects: 40
Study: 31635021

Group type: EXPERIMENTAL
Intervention: BoNT/A treatment for chronic migraine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 0
Study: 29944925

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham Acupuncture
Number of subjects: 40
Study: 27390050

Group type: EXPERIMENTAL
Intervention: Oppanol® PIB‐containing transdermal therapeutic system (TTS) formulation (0.3 mg clonidine/24 h)
Number of subjects: 58

Group type: COMPARATOR
Intervention: All patch types (T1/R1, R1/T1, T2, R2)
Number of subjects: 58
Study: 24509969

Group type: EXPERIMENTAL
Intervention: Topical scar gel containing extract of Allium cepae, allantoin, and heparin (Contractubex) applied twice daily
Number of subjects: 61

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 61
Study: 21689142

Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg for 10 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg for 10 days
Number of subjects: 90
Study: 19733106

Group type: EXPERIMENTAL
Intervention: (S)-ketamine 0.2mg/kg (group 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: (S)-ketamine 0.4mg/kg (group 2)
Number of subjects: 16
Study: 18467080

Group type: EXPERIMENTAL
Intervention: Doxorubicin-cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel-doxorubicin-cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide-doxorubicin-cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjuvant radiotherapy plus chemotherapy
Number of subjects: 0
Study: 15888514

Group type: EXPERIMENTAL
Intervention: Lamotrigine (n = 18)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 24
Study: 12742999

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 655

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 655
Study: 9881785

Group type: EXPERIMENTAL
Intervention: Tibial trephine procedure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Iliac crest harvesting
Number of subjects: 30
Study: 7844217

Group type: COMPARATOR
Intervention: Clomiphene citrate (50 mg/day for 5 days) and IUI (clomiphene/IUI group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Late low-dose pure follicle stimulating hormone (FSH, 75 IU/day from day cycle 7 until the leading follicle reached > 17 mm in diameter) and IUI (FSH/IUI group)
Number of subjects: 100
Study: 3395259

Group type: EXPERIMENTAL
Intervention: Controlled-release carbidopa/levodopa 50/200 (SINEMET CR)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard carbidopa/levodopa (SINEMET 25/100)
Number of subjects: 21
Study: 31506853

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) in addition to standard medical care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical care only
Number of subjects: 70
Study: 29907085

Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92

Group type: COMPARATOR
Intervention: Melatonin or Placebo (during withdrawal)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Irregular BZDA users
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Regular BZDA users
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Non-users
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Irregular users
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Regular users
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Whole cohort
Number of subjects: 92
Study: 28651701

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (n-3 PUFA) 2.2g/day for 26 weeks
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 26132687

Group type: EXPERIMENTAL
Intervention: D-Cycloserine plus exposure therapy (n = 20)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo plus exposure therapy (n = 16)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (D-Cycloserine and placebo)
Number of subjects: 36
Study: 24133627

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day for 6-10 months)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 34
Study: 21367625

Group type: EXPERIMENTAL
Intervention: Acarbose 50 mg three times a day (titrated to 100 mg after one month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study: 18326618

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE), 890 mg polyphenols and 366 mg EGCG, taken as 3 capsules before exercise
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (corn-flour)
Number of subjects: 23
Study: 16508253

Group type: EXPERIMENTAL
Intervention: SMOFlipid 20%
Number of subjects: 199

Group type: COMPARATOR
Intervention: Lipovenoes 20% (Control)
Number of subjects: 199